Targeting this receptor was therefore not believed to lead to unacceptable effects on haemostasis and has warranted further study.23 In keeping with this, in a recently published clinical trial of the GPVI inhibitor glenzocimab in stroke, glenzocimab was not associated with higher rates of intracranial haemorrhage than placebo.24 This evidence concerns the gene GP6 and intracranial hemorrhage.